Diabetes, pancreatic cancer, and metformin therapy

Frontiers in Physiology

Volumn 5, Issue OCT, 2014, Pages

  Gong, Jun ^a,b   Robbins, Lori A ^a,b   Lugea, Aurelia ^a,b   Waldron, Richard T ^a,b   Jeon, Christie Y ^a   Pandol, Stephen J ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Department of Medicine Veterans Affairs ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AMPK; Diabetes; IGF 1; Insulin; Metformin; mTOR; Pancreatic cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INSULIN; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; OXALIPLATIN; RAPAMYCIN;

ALCOHOL CONSUMPTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC PANCREATITIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG MECHANISM; DRUG TOLERABILITY; FUNCTIONAL STATUS; GASTROINTESTINAL TOXICITY; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; OBESITY; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SMOKING;

EID: 84908371241     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2014.00426     Document Type: Article

References (87)

1. Aggarwal, G., Kamada, P., and Chari, ST. (2013). Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42(2), 198-201. doi: 10.1097/MPA.0b013e3182592c96.
2. Aggarwal, G., Ramachandran, V., Javeed, N., Arumugam, T., Dutta, S., Klee, G.G., et al. (2012). Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in ß cells and mice. Gastroenterology 143(6), 1510-1517. doi: 10.1053/j.gastro.2012.08.044.
3. Algire, C, Moiseeva, O., Deschênes-Simard, X., Amrein, L., Petruccelli, L., Birman, E., et al. (2012). Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) 5(4), 536-543. doi: 10.1158/1940-6207.CAPR-11-0536.
4. Alsamarrai, A., Das, S.L.M., Windsor, J.A., and Petrov, M.S. (2014). Factors that affect risk for pancreatic disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol pii: S1542-3565(14), 00183-9. doi: 10.1016/j.cgh.2014.01.038.
5. Arslan, A.A., Helzlsouer, K.J., Kooperberg, C, Shu, X.O., Steplowski, E., Bueno-de-Mesquita, H.B., et al. (2010). Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 170(9), 791-802. doi: 10.1001/archinternmed.2010.63.
6. Bao, B., Wang, Z., Ali, S., Ahmad, A., Azmi, A.S., Sarkar, S.H., et al. (2012). Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res 5(3), 355-364. doi: 10.1158/1940-6207.CAPR-11-0299.
7. Bao, B., Wang, Z., Li, Y., Kong, D., Ali, S., Banerjee, S., et al. (2011). The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta 1815(2), 135-146. doi: 10.1016/j.bbcan.2010.11.003.
8. Bao, Y., Giovannucci, E.L., Kraft, P., Stampfer, M.J., Ogino, S., Ma, J., et al. (2013). A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 105(2), 95-103. doi: 10.1093/jnci/djs474.
9. Basso, D., Greco, E., Fogar, P., Pucci, P., Flagiello, A., Baldo, G, et al. (2006). Pancreatic cancer-derived S-100A8 N-terminal peptide: a diabetes cause? Clin Chim Acta 372(1-2), 120-128. Epub 2006 Mar 29. doi: 10.1016/j.cca.2006.03.027.
10. Ben, Q., Xu, M., Ning, X., Liu, J., Hong, S, Huang, W., et al. (2011). Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 47(13), 1928-1937. doi: 10.1016/j.ejca.2011.03.003.
11. Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., et al. (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25), 3576-3586. doi: 10.1038/sj.onc.1211024.
12. Ben Sahra, I., Regazzetti, C, Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., et al. (2011). Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 71(13), 4366-4372. doi: 10.1158/0008-5472.CAN-10-1769.
13. Burris, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15, 2403-2413. PMID: 9196156.
14. Campen, C.J., Dragovich, T., and Baker, A.F. (2011). Management strategies in pancreatic cancer. Am J Health Syst Pharm 68(7), 573-584. doi: 10.2146/ajhp100254.
15. Cantoria, M.J., Boros, L.G., and Meuillet, E.J. (2014). Contextual inhibition of fatty acid synthesis by metformin involves glucose-derived acetyl-CoA and cholesterol in pancreatic tumor cells. Metabolomics 10, 91-104. doi: 10.1007/s11306-013-0555-4.
16. Chari, S.T., Leibson, C.L., Rabe, K.G, Timmons, L.J., Ransom, J., de Andrade, M., et al. (2008). Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 134(1), 95-101. doi: http://dx.doi.org/10.1053/j.gastro.2007.10.040.
17. Cheng, G, Zielonka, J., McAllister, D., Tsai, S., Dwinell, M.B., and Kalyanaraman, B. (2014). Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br J Cancer 111, 85-93. doi:10.1038/bjc.2014.272.
18. Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19), 1817-1825. doi: 10.1056/NEJMoa1011923.
19. Cufí, S., Vazquez-Martin, A., Oliveras-Ferraros, C, Martin-Castillo, B., Joven, J., and Menendez, J.A. (2010). Metformin against TGFß-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis. Cell Cycle 9(22), 4461-4468. doi: 10.4161/cc.9.22.14048.
20. Currie, C.J., Poole, CD., and Gale, E.A. (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9), 1766-1777. doi: 10.1007/s00125-009-1440-6.
21. Das, A., De, A., Maity, G. Banerjee, S., and Banerjee, S. (2014). The anti-diabetic drug metformin perturbs proliferation and cellular differentiation of pancreatic cancer cells: a key mechanism of its anticancer activity (784.6). The FASEB Journal 28, 784-786.
22. De La Cruz, M.S., Young, A.P., and Ruffin, M.T. (2014). Diagnosis and management of pancreatic cancer. Am Fam Physician 89(8), 626-632. PubMed PMID: 24784121.
23. Ding, X.Z., Fehsenfeld, D.M., Murphy, L.O., Permert, J., and Adrian, T.E. (2000). Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas 21(3), 310-320. PubMed PMID: 11039477.
24. Draznin, B. (2011). Mechanism of the mitogenic influence of hyperinsulinemia. Diabetol Metab Syndr 3(1), 10. doi: 10.1186/1758-5996-3-10.
25. Elena, J.W., Steplowski, E., Yu, K., Hartge, P., Tobias, G.S., Brotzman MJ, et al. (2013). Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Cancer Causes Control 24(1), 13-25. doi: 10.1007/s10552-012-0078-8.
26. El-Mir, M.Y., Nogueira, V., Fontaine, E., Avéret, N., Riqoulet, M., and Leverve, X. (2000). Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275(1), 223-228. Pubmed PMID: 10617608.
27. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., and Morris AD. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503), 1304-1305. doi: http://dx.doi.org/10.1136/bmj.38415.708634.F7.
28. Everhart J., and Wright, D. (1995). Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 273(20), 1605-1609. doi: 10.1001/jama.1995.03520440059037.
29. Fasih, A., Elbaz, H.A., Hüttemann, M., Konski, A.A., and Zielske S.P. (2014). Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res 182(1), 50-59. doi: 10.1667/RR13568.1.
30. Fogar, P., Pasquali, C., Basso, D., Sperti, C., Panozzo, M.P., Tessari, G., et al. (1994). Diabetes mellitus in pancreatic cancer follow-up. Anticancer Res 14(6B), 2827-2830. PubMed PMID: 7532931.
31. Genkinger, J.M., Spiegelman, D., Anderson, K.E., Bernstein, L., van den Brandt, P.A., Calle, E.E., et al. (2011). A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer 129(7), 1708-1717. doi: 10.1002/ijc.25794.
32. Ghosn, M., Kourie, H.R., El Karak, F., Hanna, C., Antoun, J., and Nasr, D. (2014). Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol 20(9), 2352-2357. doi: 10.3748/wjg.v20.i9.2352.
33. Godsland, I.F. (2009). Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond) 118(5),315-332. doi: 10.1042/CS20090399.
34. Gou, S., Cui, P., Li, X., Shi, P., Liu, T., and Wang, C. (2013). Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One 8(5), e63969. doi: 10.1371/journal.pone.0063969.
35. Hirsch, H.A., Iliopoulos, D., and Struhl, K. (2013). Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 110(3), 972-977. doi: 10.1073/pnas.1221055110.
36. Howlader, N., Noone, A.M., Krapcho, M., Garshell, J., Miller, D., Altekruse, S.F., et al. ed. (2014). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
37. Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., and Woodward M. (2005). Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92(11), 2076-2083. doi: 10.1038/sj.bjc.6602619.
38. Iliopoulos, D., Hirsch, H.A., and Struhl, K. (2011). Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 71(9), 3196-3201. doi: 10.1158/0008-5472.CAN-10-3471.
39. Iodice, S., Gandini, S., Maisonneuve, P., and Lowenfels, A.B. (2008). Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393(4), 535-545. doi: 10.1007/s00423-007-0266-2.
40. Jalving, M., Gietema, J.A., Lefrandt, J.D., de Jong, S., Reyners, A.K., Gans, R.O., et al. (2010). Metformin: taking away the candy for cancer? Eur J Cancer 46(13), 2369-2380. doi: 10.1016/j.ejca.2010.06.012.
41. Jiao, L., Berrington de Gonzalez, A., Hartge, P., Pfeiffer, R.M., Park, Y., Freedman, D.M., et al. (2010). Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. Cancer Causes Control 21(8), 1305-1314. doi: 10.1007/s10552-010-9558-x.
42. Kalender, A., Selvaraj, A., Kim, S.Y., Gulati, P., Brûlé, S., Viollet, B., et al. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11(5), 390-401. doi: 10.1016/j.cmet.2010.03.014.
43. Karnevi, E., Said, K., Andersson, R., and Rosendahl, A.H. (2013). Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer 13, 325. doi: 10.1186/1471-2407-13-235.
44. Kisfalvi, K., Eibl, G., Sinnett-Smith, J., and Rozengurt, E. (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69, 6539-6545. doi: 10.1158/0008-5472.CAN-09-0418.
45. Kisfalvi, K., Moro, A., Sinnett-Smith, J., Eibl, G., and Rozengurt, E. (2013). Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas 42(5), 781-785. doi: 10.1097/MPA.0b013e31827aec40.
46. Kirk, R. (2012). Pancreatic cancer: mouse models link metabolism and deubiquitination with Kras. Nat Rev Clin Oncol 9(7), 368. doi:10.1038/nrclinonc.2012.85.
47. Larsson, S.C., Orsini, N., and Wolk, A. (2007). Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer 120(9), 1993-1998. doi: 10.1002/ijc.22535.
48. Li, D,. (2012). Diabetes and pancreatic cancer. Mol Carcinog 51(1), 64-74. doi: 10.1002/mc.20771.
49. Li, W., Yuan, Y., Huang, L., Qiao, M., and Zhang, Y. (2012). Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract 96(2), 187-195. doi: 10.1016/j.diabres.2011.12.028.
50. Lonardo, E., Cioffi, M., Sancho, P., Sanchez-Ripoll, Y., Trabulo, S.M., Dorado, J., et al. (2013). Metformin targets the metabolic Achilles heel of human pancreatic cancer stem cells. PLOS One 8(10), e76518. doi:10.1371/journal.pone.0076518.
51. Lowenfels, A.B., Maisonneuve, P., DiMagno, E.P., Elitsur, Y., Gates, L.K., Jr, Perrault, J., et al. (1997). Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 89(6), 442-446. doi: 10.1093/jnci/89.6.442.
52. Ma, J., Sawai, H., Matsuo, Y., Ochi, N., Yasuda, A., Takahashi, H., et al. (2010). IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF 1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res 160(1), 90-101. doi: 10.1016/j.jss.2008.08.016.
53. Mohammed, A., Janakiram, N.B., Brewer, M., Ritchie, R.L., Marya, A., Lightfoot, S., et al. (2013). Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol 6(6), 649-659. Pubmed PMID: 24466367.
54. Morran, D.C., Wu, J., Jamieson, N.B., Mrowinska, A., Kalna, G., Karim, S.A., et al. (2014). Targeting mTOR dependency in pancreatic cancer. Gut 0, 1-9. doi:10.1136/gutjnl-2013-306202.
55. Nair, V., Pathi, S., Jutooru, I., Sreevalsan, S., Basha, R., Abdelrahim, M., et al. (2013). Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis 34(12), 2870-2879. doi: 10.1093/carcin/bgt231.
56. Nair, V., Sreevalsan, S., Basha, R., Abdelrahim, M., Abudayyeh, A., Hoffman, A.R., et al. (2014). Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem 289(40), 27692-27701. doi: 10.1074/jbc.M114.592576.
57. Nakamura, M., Ogo, A., Yamura, M., Yamaguchi, Y., and Nakashima, H. (2014). Metformin suppresses Sonic hedgehog expression in pancreatic cancer cells. Anticancer Research 34(4), 1765-1769. Pubmed PMID: PMID: 24692708.
58. Pannala, R., Leirness, J.B., Bamlet, W.R., Basu, A., Petersen, G.M., and Chari, S.T. (2008). Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 134(4), 981-987. doi: 10.1053/j.gastro.2008.01.039.
59. Permert, J., Ihse, I., Jorfeldt, L., von Schenck, H., Arnquist, H.J., and Larsson, J. (1993). Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 80(8), 1047-1050. doi: 10.1002/bjs.1800800841.
60. Permert, J., Ihse, I., Jorfeldt, L., von Schenck, H., Arnqvist, H.J., and Larsson, J. (1993). Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 159(2), 101-107. PubMed PMID: 8098623.
61. Permert, J., Larsson, J., Westermark, G.T., Herrington, M.K., Christmanson, L., Pour, P.M., et al. (1994). Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med 330(5), 313-318. doi: 10.1056/NEJM199402033300503.
62. Pollak, M.N., Schernhammer, E.S., and Hankinson, S.E. (2004). Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7), 505-518. doi: 10.1038/nrc1387.
63. Powell, D.R., Suwanichkul, A., Cubbage, M.L., DePaolis, L.A., Snuggs, M.B., and Lee, P.D. (1991). Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem 266(28), 18868-18876. PubMed PMID: 1717456.
64. Raimondi, S., Lowenfels, A.B., Morselli-Labate, A.M., Maisonneuve, P., and Pezzilli, R. (2010). Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24(3), 349-358. doi: 10.1016/j.bpg.2010.02.007.
65. Rozengurt, E. (2014). Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Front Physiol 5(357), 1-8. doi: 10.3389/fphys.2014.00357.
66. Rozengurt, E., Sinnett-Smith, J., and Kisfalvi, K. (2010). Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16, 2505-2511. doi: 10.1158/1078-0432.CCR-09-2229.
67. Saborowski, M., Saborowski, A., Morris, J.P., Bosbach, B., Dow, L.E., Pelletier, J., et al. (2014). A modular and flexible ESC-based mouse model of pancreatic cancer. Genes & Dev 28(1), 85-97. doi: 10.1101/gad.232082.113.
68. Sadeghi, N., Abbruzzese, J.L., Yeung, S.J., Hassan, M., and Li, D. (2012). Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 18(10), 2905-2912. doi: 10.1158/1078-0432.CCR-11-2994.
69. Sah, R.P., Nagpal, S.J., Mukhopadhyay, D., and Chari, S.T. (2013). New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol 10(7), 423-433. doi: 10.1038/nrgastro.2013.49.
70. Schneider, M.B., Matsuzaki, H., Haorah, J., Ulrich, A., Standop, J., Ding XZ, et al. (2001). Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120(5), 1263-1270. doi: http://dx.doi.org/10.1053/gast.2001.23258.
71. Seufferlein, T., Bachet, J.B., Van Cutsem, E., and Rougier, P. (2012). Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 23(Suppl 7), 733-740. doi: 10.1093/annonc/mds224.
72. Sinnett-Smith, J., Kisfalvi, K., Kui, R., and Rozengurt, E. (2012). Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun 430(1), 352-357. doi: 10.1016/j.bbrc.2012.11.010.
73. Snima, K.S., Jayakumar, R., Lakshmanan, V.K. (2014). In vitro and in vivo biological evaluation of O-carboxymethyl chitosan encapsulated metformin nanoparticles for pancreatic cancer therapy. Pharm Res 2014, 1-10. doi: 10.1007/s11095-014-1425-0.
74. Snima, K.S., Jayakumar, R., Unnikrishnan, A.G., Nair, S.V., and Lakshmanan, V.K. (2012). OCarboxymethyl chitosan nanoparticles for metformin delivery to pancreatic cancer cells. Carbohydrate Polymers 89(3), 1003-1007. doi: 10.1016/j.carbpol.2012.04.050.
75. Soares, H.P., Ni, Y., Kisfalvi, K., Sinnett-Smith, J., and Rozengurt, E. (2013). Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLOS One 8(2), e57289. doi: 10.1371/journal.pone.0057289.
76. Son, J., Lyssiotis, C.A., Ying, H., Wang, X., Hua, S., Ligorio, M., et al. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101-105. doi:10.1038/nature12040.
77. Tramacere, I., Scotti, L., Jenab, M., Bagnardi, V., Bellocco, R., Rota, M., et al. (2010). Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer 126(6), 1474-1486. doi: 10.1002/ijc.24936.
78. Viale, A., Pettazzoni, P., Lyssiotis, C.A., Ying, H., Sánchez, N., Marchesini, M., et al. (2014). Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014, 1-8. doi:10.1038/nature13611.
79. Wang, L.W., Li, Z.S., Zou, D.W., Jin, Z.D., Gao, J., and Xu, G.M. (2008). Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14(47), 7192-7198. doi: 10.3748/wjg.14.7192.
80. Wang, Z., Lai, S.T., Xie, L., Zhao, J.D., Ma, N.Y., Zhu, J., et al. (2014). Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract pii:S0168-8227(14), 00190-00199. doi: 10.1016/j.diabres.2014.04.007.
81. White, M.A., Agle, S.C., Fuhr, H.M., Mehaffey, J.H., Waibel, B.H., and Zervos, E.E. (2011). Impact of pancreatic cancer and subsequent resection on glycemic control in diabetic and nondiabetic patients. Am Surg 77(8), 1032-1037. PubMed PMID: 21944519.
82. Wolpin, B.M., Bao, Y., Qian, Z.R., Wu, C, Kraft, P., Ogino, S., et al. (2013). Hyperglycemia, insulin resistance, impaired pancreatic ß-cell function, and risk of pancreatic cancer. J Natl Cancer Inst 105(14), 1027-1035. doi: 10.1093/jnci/djt123.
83. Yan, G., Freeman, T., and Lanza-Jacoby, S. (2013). Limiting glucose availability with metformin increased reactive oxygen species, decreased cell survival, and promoted apoptosis in human and mouse pancreatic cancer cells. Cancer Res 73(8 Suppl 1), abstrnr 5405. doi: 10.1158/1538-7445.AM2013-5405.
84. Ying, H., Elpek, K.G., Vinjamoori, A., Zimmerman, S.M., Chu, G.C., Yan, H., et al. (2011). PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-?Bcytokine network. Cancer Disc 1(2), 158-169. doi: 10.1158/2159-8290.CD-11-0031.
85. Yue, W., Yang, C.S., DiPaola, R.S., and Tan, X.L. (2014). Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res 7(4), 388-397. doi: 10.1158/1940-6207.CAPR-13-0337.
86. Zhao, Z., Cheng, X., Wang, Y., Han, R, Li, L., Xiang, T., et al. (2014). Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One 9(4), e95884. doi: 10.1371/journal.pone.0095884.
87. Zou, L., Zhong, R., Shen, N., Chen, W., Zhu, B., Ke, J., et al. (2014). Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a metaanalysis of 42 observational studies. Eur J Cancer 50(1), 193-203. doi: 10.1016/j.ejca.2013.08.014.